Incidence of cancer in postmyocardial infarction patients treated with short-acting nifedipine and diltiazem

Cancer

Volumn 85, Issue 6, 1999, Pages 1369-1374

  Kanamasa, Ken ^a   Kimura, Akio ^a   Miyataka, Masaru ^a   Takenaka, Toshihiko ^a   Ishikawa, Kinji ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cancer; Diltiazem; Myocardial infarction; Nifedipine

Indexed keywords

CALCIUM ANTAGONIST; DILTIAZEM; NIFEDIPINE;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER RISK; DRESSLER SYNDROME; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT;

CALCIUM CHANNEL BLOCKERS; CAUSE OF DEATH; DILTIAZEM; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NEOPLASMS; NIFEDIPINE; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; RISK FACTORS;

EID: 0033559227     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990315)85:6<1369::AID-CNCR21>3.0.CO;2-5     Document Type: Article

References (26)

1. Pahor M, Guralnik JM, Corti M-C, Foley DJ, Carbonin P, Havlik RJ, Long-term survival and use of antihypertensive medications in older persons. J Am Geriatr Soc 1995;43: 1191-7.
2. Furberg CD, Psaty BM. Calcium antagonists: antagonists or protagonists of mortality in elderly hypertensives? J Am Geriatr Soc 1995;43:1309-10.
3. Pahor M, Guralnik JM, Ferrucci L, Corti M-C, Salive ME, Cerhan JR, et al. Calcium-channel blockade and incidence of cancer in aged populations. Lancet 1996;348:493-7.
4. Pahor M, Guralnik JM, Salive ME, Corti M-C, Carbonin P, Havlik RJ. Do calcium channel blockers increase the risk of cancer? Am J Hypertens 1996;9:695-9.
5. Fitzpatrick AL, Daling JR, Furberg CD, Kronmal RA, Weissfeld JL. Use of calcium channel blockers and breast carcinoma risk in postmenopausal women. Cancer 1997;80: 1438-47.
6. Kondo S, Yin D, Morimura T, Kubo H, Nakatsu S, Takeuchi J. Combination therapy with cisplatin and nifedipine induces apoptosis in cisplatin-sensitive and cisplatin-resistant human glioblastoma cells. Br J Cancer 1995;71:282-9.
7. Gong L, Zhang W, Zhu Y, Zhu J, 11 collaborating centres in the Shanghai area, Kong D, Page V, et al. Shanghai trial of nifedipine in the elderly (STONE). J Hypertens 1996;14:1237-45.
8. Braun S, Boyko V, Behar S, Reicher-Reiss H, Shotan A, Schlesinger Z, et al. Calcium antagonists and mortality in patients with coronary artery disease: a cohort study of 11, 575 patients. J Am Coll Cardiol 1996;28:7-11.
9. Jick H, Jick S, Derby LE, Vasilakis C, Myers MW, Meier CR. Calcium-channel blockers and risk of cancer. Lancet 1997; 349:525-8.
10. Jonas M, Goldbourt U, Behar S, Boyko V, Shotan A, Reicher-Reiss H on behalf of the SPRINT study group. Nifedipine and cancer: ten-year mortality follow-up of 4,808 patients after acute myocardial infarction. Eur Heart J 1997; 18(Suppl):67.
11. Olsen JH, Sorensen HT, Friis S, McLaughlin JK, Steffensen FH, Nielsen GL, et al. Cancer risk in users of calcium channel blockers. Hypertension 1997;29:1091-4.
12. Ad hoc subcommittee of the liaison committee of the World Health Organisation and the International Society of Hypertension. Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding. J Hypertens 1997; 15:105-15.
13. Ishikawa K, Nakai S, Takenaka T, Kanamasa K, Hama J, Ogawa I, et al. Short-acting nifedipine and diltiazem do not reduce the incidence of cardiac events in patients with healed myocardial infarction. Circulation 1997;95:2368-73.
14. Barger-Lux MJ, Heaney RP. The role of calcium intake in preventing bone fragility, hypertension, and certain cancers. J Nutr 1994;124:1406S-11S.
15. Hardell L, Fredrikson M, Axelson O. Case-control study on colon cancer regarding previous diseases and drug intake. Int J Oncol 1996;8:439-44.
16. Kondo S, Yin D, Morimura T, Takeuchi J. Combination therapy with cisplatin and nifedipine inducing apoptosis in multidrug-resistant human glioblastoma cells. J Neurosurg 1995;82:469-74.
17. Chow W-H, McLaughlin JK, Mandel JS, Wacholder S, Niwa S, Fraumeni JF Jr. Risk of renal cell cancer in relation to diuretics, antihypertensive drugs, and hypertension. Cancer Epidemiol Biomarkers 1995;4:327-31.
18. Messerli FH. Safety of calcium antagonists: dissecting the evidence. Am J Cardiol 1996;78(Suppl 9A):19-23.
19. Alderman MH. More news about calcium antagonists. Am J Hypertens 1996;9:710-2.
20. Daling JR. Calcium channel blockers and cancer: is an association biologically plausible? Am J Hypertens 1996;9: 713-4.
21. Alderman MH. Hypertension and how to treat it: studies good and bad and a strategic suggestion. Am J Hypertens 1996;9:715-7.
22. Kaplan NM. Letters to the editor: do calcium antagonists cause cancer? Lancet 1996;348:541.
23. Bursch W, Oberhammer F, Schulte-Hermann R. Cell death by apoptosis and its protective role against disease. Trends Pharmacol Sci 1992;13:245-51.
24. Correale P, Tagliaferri P, Celio L, Genua G, Montagnani S, Bianco AR. Verapamil upregulates sensitivity of human colon and breast cancer cells to LAK-cytotoxicity in vitro. Eur J Cancer 1991;27:1393-5.
25. Kehinde EO, Petermann A, Morgan JD, Butt ZA, Donnelly PK, Veitch PS, et al. Triple therapy and incidence of de novo cancer in renal transplant recipients. Br J Surg 1994;81: 985-6.
26. 2+ channel antagonists. Mol Chem Neuropathol 1994;22:81-95.